Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Scott Miller

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Gynecologic Oncology|December 7, 2002
A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group studyDavid Scott Miller, John A Blessing, Samuel S Lentz, et al.
Cancer|October 10, 2003
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group studyDavid Scott Miller, John A Blessing, Samuel S Lentz, et al.
Cancers|February 11, 2023
Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer TreatmentIgnace Vergote, Teresa Macarulla, Fred R Hirsch, et al.
Gynecologic Oncology|June 25, 2005
Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group studyDavid Scott Miller, John A Blessing, Jeanne Schilder, et al.
Gynecologic Oncology|February 3, 2024
Social determinants of health in uterine carcinosarcomaLarissa L Aroche Gutierrez, Donald D McIntire, Jayanthi Lea, et al.
Archives of Pathology & Laboratory Medicine|June 26, 2003
Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literatureVilkesh R Jaiswal, Julie Baird, Jason Fleming, et al.
Expert Opinion on Pharmacotherapy|July 10, 2009
Pharmacotherapy of endometrial cancerNicanor I Barrena Medel, Sharmilee Bansal, David Scott Miller, et al.
Gynecologic Oncology|May 6, 2008
Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupDavid Scott Miller, John A Blessing, Diane C Bodurka, et al.
Gynecologic Oncology Research and Practice|December 8, 2017
New therapies for advanced, recurrent, and metastatic endometrial cancersVicky Makker, Angela K Green, Robert M Wenham, et al.
Gynecologic Oncology|December 14, 2004
Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group StudyDavid Scott Miller, John A Blessing, Steven Waggoner, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Gynecologic Oncology|December 7, 2002
A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group studyDavid Scott Miller, John A Blessing, Samuel S Lentz, et al.
Cancer|October 10, 2003
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group studyDavid Scott Miller, John A Blessing, Samuel S Lentz, et al.
Cancers|February 11, 2023
Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer TreatmentIgnace Vergote, Teresa Macarulla, Fred R Hirsch, et al.
Gynecologic Oncology|June 25, 2005
Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group studyDavid Scott Miller, John A Blessing, Jeanne Schilder, et al.
Gynecologic Oncology|February 3, 2024
Social determinants of health in uterine carcinosarcomaLarissa L Aroche Gutierrez, Donald D McIntire, Jayanthi Lea, et al.
Archives of Pathology & Laboratory Medicine|June 26, 2003
Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literatureVilkesh R Jaiswal, Julie Baird, Jason Fleming, et al.
Expert Opinion on Pharmacotherapy|July 10, 2009
Pharmacotherapy of endometrial cancerNicanor I Barrena Medel, Sharmilee Bansal, David Scott Miller, et al.
Gynecologic Oncology|May 6, 2008
Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupDavid Scott Miller, John A Blessing, Diane C Bodurka, et al.
Gynecologic Oncology Research and Practice|December 8, 2017
New therapies for advanced, recurrent, and metastatic endometrial cancersVicky Makker, Angela K Green, Robert M Wenham, et al.
Gynecologic Oncology|December 14, 2004
Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group StudyDavid Scott Miller, John A Blessing, Steven Waggoner, et al.
Pageof 4